Business Context and Reporting Period
Company: Biorestorative Therapies, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 20, 2020
Reporting Period: Events occurring between February 11, 2020, and February 20, 2020.
Status: Emerging Growth Company.
Key Financial Metrics
This filing reports a specific capital transaction rather than periodic financial performance. The filing text does not provide clear values for revenue, profit, cash flow, margins, or liquidity.
- Debt Converted: $327,123 (aggregate amount of indebtedness, inclusive of accrued and unpaid interest and imputed additional principal).
- Shares Issued: 327,123,339 shares of common stock.
- Total Outstanding Shares: Approximately 1,328,000,000 shares following the issuance.
Material Changes
The primary material change reported is the unregistered sale of equity securities via the conversion of debt.
- Transaction: Holders of convertible promissory notes exercised conversion rights.
- Impact on Capital Structure: The company eliminated $327,123 in debt obligations in exchange for issuing a significant volume of common stock (327,123,339 shares).
- Legal Basis: Transactions relied upon Section 4(a)(2) and Section 3(a)(9) of the Securities Act of 1933 as private placements/exchanges with existing security holders.
Guidance, Outlook, and Risks
The filing text does not provide forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the transaction mechanics.
- Investor Status: The Company reasonably believes all investors in this transaction are accredited investors.
- Disclosure: No general solicitation or advertising was used; investors had access to historical reports (10-K, 10-Q, 8-K) and press releases.
Investor Verification Checklist
- Verify the dilution impact of issuing 327,123,339 shares on existing shareholders.
- Confirm the total number of outstanding shares (approx. 1.328 billion) against subsequent filings.
- Review the terms of the convertible promissory notes to understand the conversion rate and accrued interest calculations.
- Assess the company's remaining cash position and liquidity needs post-conversion, as this filing does not disclose current cash balances.